Comparison of multiple oncotype DX® from the same patient

Ashley D Marumoto; Srivarshini C Mohan; Stephanie A K Angarita; Marissa K Srour; Vicky E Norton; Farnaz Dadmanesh; Armando E Giuliano

doi:10.1111/tbj.14288

Comparison of multiple oncotype DX^® from the same patient

Breast J. 2021 Nov;27(11):828-831. doi: 10.1111/tbj.14288. Epub 2021 Sep 12.

Authors

Ashley D Marumoto¹, Srivarshini C Mohan¹, Stephanie A K Angarita¹, Marissa K Srour¹, Vicky E Norton¹, Farnaz Dadmanesh², Armando E Giuliano¹

Affiliations

¹ Cedars-Sinai Medical Center, Department of Surgery, Los Angeles, CA, USA.
² Cedars-Sinai Medical Center, Department of Pathology and Laboratory Medicine, Los Angeles, CA, USA.

PMID: 34514676
DOI: 10.1111/tbj.14288

Abstract

For women with breast cancer in whom multiple Oncotype DX^® Recurrence Scores (RS) are obtained, RS concordance utilizing current NCCN recommendations has not been evaluated. Patients with two or more RS were identified. RS were stratified by NCCN guidelines and compared for concordance. Twenty-four patients were evaluated. RS concordance varied by tumor type: 100% in the same tumor, 91.7% in multiple ipsilateral tumors, 71.4% in contralateral tumors, and 66.7% in in-breast recurrent tumors. RS concordance for multiple assays in the same patient is not high enough to omit Oncotype DX^® testing for each tumor.

Keywords: breast cancer; multiple oncotype DX®; recurrence score.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers, Tumor / genetics
Breast Neoplasms* / genetics
Female
Gene Expression Profiling
Humans
Neoplasm Recurrence, Local / genetics
Prognosis

Substances

Biomarkers, Tumor